Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CryoPort, Inc. CYRX

Industrials  —  Integrated Freight & Logistics
17.41 0.01 0.06% as of 25 Sep
Market cap
$881.3M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

CryoPort, Inc. (CYRX) Business Profile

Updated before January 2025

Company Overview

CryoPort, Inc. (NASDAQ: CYRX) is a leading provider of temperature-controlled supply chain solutions for the life sciences industry. Founded in 1999 and headquartered in Brentwood, Tennessee, CryoPort specializes in providing innovative logistics solutions for the biopharmaceutical, reproductive medicine, and animal health sectors. The company has established itself as a critical partner for organizations requiring precise temperature control and monitoring during the transportation of sensitive biological materials.

CryoPort’s leadership team is composed of experienced professionals with deep expertise in logistics, biotechnology, and supply chain management. Jerrell Shelton serves as the President and Chief Executive Officer, bringing decades of leadership experience in technology and life sciences. Under his guidance, CryoPort has expanded its global footprint and diversified its service offerings to meet the growing demands of the life sciences industry.

Core Business Segments

CryoPort operates through three primary business segments, each catering to specific needs within the life sciences industry:

1. Biopharma/Pharma Solutions

CryoPort provides temperature-controlled logistics solutions for biopharmaceutical companies, including those involved in cell and gene therapies, clinical trials, and commercialized biologics. Key offerings include:

  • Cryoport Express® Shippers: Advanced shipping containers designed to maintain ultra-low temperatures for extended periods.
  • Cryoportal® Logistics Management Platform: A cloud-based platform that enables real-time tracking, monitoring, and management of shipments.
  • Temperature-Controlled Storage: Facilities for short- and long-term storage of biological materials at ultra-low temperatures.

2. Reproductive Medicine

CryoPort supports fertility clinics and reproductive medicine centers by providing specialized logistics solutions for the transportation of reproductive materials such as embryos, eggs, and sperm. Key services include:

  • CryoStork® Services: End-to-end logistics solutions tailored for the reproductive medicine industry.
  • Secure Transport Containers: Designed to ensure the safe and reliable transportation of sensitive reproductive materials.

3. Animal Health

CryoPort extends its expertise to the animal health sector, offering logistics solutions for the transportation of veterinary biologics, vaccines, and other temperature-sensitive materials. This segment is growing as the demand for advanced veterinary care increases globally.

Business Model

CryoPort’s business model revolves around integrating its proprietary products and services to create a comprehensive temperature-controlled logistics ecosystem. The company generates revenue through:

  • Product Sales: Selling advanced shipping containers and related equipment.
  • Service Contracts: Offering logistics management, monitoring, and storage services on a subscription or per-use basis.
  • Consulting Services: Providing expertise in supply chain optimization and regulatory compliance for life sciences companies.

CryoPort’s ability to combine cutting-edge technology with exceptional customer service has positioned it as a trusted partner for organizations navigating the complexities of temperature-sensitive logistics.

Strategic Direction

CryoPort is focused on expanding its global presence and enhancing its service offerings to meet the evolving needs of the life sciences industry. Key strategic initiatives include:

  • Geographic Expansion: Establishing new facilities and partnerships in emerging markets to support global clinical trials and commercial operations.
  • Service Diversification: Developing new solutions for adjacent markets, such as personalized medicine and advanced therapies.
  • Sustainability Goals: Investing in eco-friendly technologies and practices to reduce the environmental impact of its operations.
  • Innovation: Continuing to enhance its Cryoportal® platform and shipping technologies to improve efficiency and reliability.

Competitive Landscape

CryoPort operates in a competitive market, facing challenges from both established players and emerging startups. Key competitors include:

  • Thermo Fisher Scientific: A global leader in scientific research and logistics solutions.
  • BioLife Solutions: Specializes in biopreservation media and logistics services for cell and gene therapies.
  • World Courier: A division of AmerisourceBergen, offering global logistics solutions for the pharmaceutical industry.
  • Marken: A UPS company providing supply chain solutions for clinical trials and pharmaceutical logistics.

CryoPort differentiates itself through its focus on innovation, customer service, and end-to-end logistics solutions tailored specifically for the life sciences industry.

Risk Factors

CryoPort faces several risks that could impact its business operations and financial performance, including:

  • Market Dependence: Reliance on the biopharmaceutical industry, which is subject to regulatory changes and market fluctuations.
  • Supply Chain Disruptions: Potential delays or shortages in the availability of critical components and materials.
  • Technological Obsolescence: The need to continuously innovate to stay ahead of competitors.
  • Economic Conditions: Global economic downturns could reduce demand for CryoPort’s services.

Recent Developments

CryoPort has made significant strides in recent years, including:

  • Acquisitions: Acquiring companies such as MVE Biological Solutions and CRYOPDP to expand its capabilities and market reach.
  • New Facilities: Opening state-of-the-art logistics centers in key markets, including Europe and Asia.
  • Technological Advancements: Enhancing its Cryoportal® platform with new features for improved tracking and analytics.
  • COVID-19 Impact: Supporting the global distribution of COVID-19 vaccines and therapies, which highlighted the importance of temperature-controlled logistics.

Investment Considerations

Investors considering CryoPort should weigh the following strengths and risks:

Strengths:

  • Market Leadership: A strong position in the growing temperature-controlled logistics market.
  • Innovative Technology: Proprietary solutions that set CryoPort apart from competitors.
  • Diverse Revenue Streams: A mix of product sales, service contracts, and consulting services.
  • Global Presence: A robust network of facilities and partnerships worldwide.

Risks:

  • Regulatory Challenges: Compliance with stringent regulations in the life sciences industry.
  • Economic Sensitivity: Vulnerability to economic downturns and budget constraints in the healthcare sector.
  • Competition: Intense competition from established players and new entrants.

Conclusion

CryoPort, Inc. is a leader in temperature-controlled logistics solutions for the life sciences industry, with a strong focus on innovation, customer service, and global expansion. The company’s comprehensive product and service offerings position it well to capitalize on the growing demand for advanced logistics solutions in biopharma, reproductive medicine, and animal health. While challenges such as regulatory compliance and competition remain, CryoPort’s strategic initiatives and commitment to excellence make it a compelling choice for investors and partners alike.